Evidence map›Paper›PMID 28270091›Full record

ArticleBMC evolutionary biology2017

Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.

Lize Cuypers, Bram Vrancken, Lavinia Fabeni, Nadia Marascio, Valeria Cento, Velia Chiara Di Maio, Marianna Aragri, Andrea Clemencia Pineda-Peña, Yoeri Schrooten, Kristel Van Laethem and 7 more

Abstract read
In one paragraph

Article in BMC evolutionary biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Dynamics and Dispersal of Local Human Immunodeficiency Virus Epidemics Within San Diego and Across the San Diego-Tijuana Border.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lize CuypersKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium. lize.cuypers@kuleuven.be.
Bram VranckenKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium.
Lavinia FabeniNational Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.
Nadia MarascioKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium.
Valeria CentoDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Velia Chiara Di MaioDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Marianna AragriDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Andrea Clemencia Pineda-PeñaGlobal Health and Tropical Medicine, GHTM, Institute for Hygiene and Tropical Medicine, IHMT, University Nova de Lisboa, UNL, Rua da Junqueira 100, 1349-008, Lisbon, Portugal.
Yoeri SchrootenKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium.
Kristel Van LaethemKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium.
Daniel BalogLuciad, Computer Software, Gaston Geenslaan 11, 3001, Heverlee, Belgium.
Alfredo FocàDepartment of Health Sciences, Institute of Microbiology, School of Medicine, University of "Magna Graecia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Carlo TortiDepartment of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, School of Medicine, University of "Magna Graecia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Frederik NevensKU Leuven - University of Leuven, Department of Clinical and Experimental Medicine, Hepatology, Leuven, Belgium.
Carlo Federico PernoDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Anne-Mieke VandammeKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Herestraat 49 - box 1040, 3000, Leuven, Belgium.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn-depth phylogeographic analysis can reveal migration patterns relevant for public health planning. Here, as a model, we focused on the provenance, in the current Italian HCV subtype 1a epidemic, of the NS3 resistance-associated variant (RAV) Q80K, known to interfere with the action of NS3/4A protease inhibitor simeprevir. HCV1a migration patterns were analysed using Bayesian phylodynamic tools, capitalising on newly generated and publicly available time and geo-referenced NS3 encoding virus genetic sequence data.

resultsOur results showed that both immigration and local circulation fuel the current Italian HCV1a epidemic. The United States and European continental lineages dominate import into Italy, with the latter taking the lead from the 1970s onwards. Since similar migration patterns were found for Q80K and other lineages, no clear differentiation of the risk for failing simeprevir can be made between patients based on their migration and travel history. Importantly, since HCV only occasionally recombines, these results are readily transferable to the genetic sequencing policy concerning NS5A RAVs.

conclusionsThe patient migration and travel history cannot be used to target only part of the HCV1a infected population for drug resistance testing before start of antiviral therapy. Consequently, it may be cost-effective to expand genotyping efforts to all HCV1a infected patients eligible for simeprevir-based therapies.

Indexed as

Antiviral AgentsBayes TheoremDrug Resistance, ViralGenotypeHepacivirusHepatitis CHumansItalySimeprevirAntiviral AgentsSimeprevirEuropeHCVHCV1aItalyPhylogeographyPublic health policyQ80KUS

Identifiers

PMID28270091
PMCPMC5341469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.